CU20210081A7 - Composición de partículas de arn lipoplejo - Google Patents

Composición de partículas de arn lipoplejo

Info

Publication number
CU20210081A7
CU20210081A7 CU2021000081A CU20210081A CU20210081A7 CU 20210081 A7 CU20210081 A7 CU 20210081A7 CU 2021000081 A CU2021000081 A CU 2021000081A CU 20210081 A CU20210081 A CU 20210081A CU 20210081 A7 CU20210081 A7 CU 20210081A7
Authority
CU
Cuba
Prior art keywords
composition
rna particles
lipoplex
percent
concentration
Prior art date
Application number
CU2021000081A
Other languages
English (en)
Inventor
Heinrich Haas
Thomas Michael Hiller
Sebastian Hörner
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of CU20210081A7 publication Critical patent/CU20210081A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente solicitud se refiere a una composición que comprende partículas de ARN lipoplejo que comprenden ARN y un lípido catiónico y un lípido adicional, cloruro de sodio a una concentración de 10 mM o menos, un estabilizador a una concentración del 10 porciento en peso por porcentaje en volumen ( porciento p/v) o menos, y un búfer.</p>
CU2021000081A 2019-04-05 2020-04-01 Composición de partículas de arn lipoplejo CU20210081A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/058635 WO2020200472A1 (en) 2019-04-05 2019-04-05 Preparation and storage of liposomal rna formulations suitable for therapy
PCT/EP2020/059308 WO2020201383A1 (en) 2019-04-05 2020-04-01 Preparation and storage of liposomal rna formulations suitable for therapy

Publications (1)

Publication Number Publication Date
CU20210081A7 true CU20210081A7 (es) 2022-05-11

Family

ID=66223673

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000081A CU20210081A7 (es) 2019-04-05 2020-04-01 Composición de partículas de arn lipoplejo

Country Status (18)

Country Link
US (1) US12433911B2 (es)
EP (1) EP3946255B1 (es)
JP (1) JP7692837B2 (es)
KR (1) KR20210148162A (es)
CN (1) CN113924082B (es)
AU (1) AU2020255262A1 (es)
BR (1) BR112021020011A2 (es)
CA (1) CA3134211A1 (es)
CL (1) CL2021002557A1 (es)
CO (1) CO2021013376A2 (es)
CU (1) CU20210081A7 (es)
DK (1) DK3946255T3 (es)
ES (1) ES3008537T3 (es)
IL (1) IL285811A (es)
MX (1) MX2021012138A (es)
SG (1) SG11202109164WA (es)
WO (2) WO2020200472A1 (es)
ZA (1) ZA202106237B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020200472A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
JP7804305B2 (ja) 2020-09-24 2026-01-22 Ｆｕｔｕｒｅ Ｔｅｃｈｎｏｌｏｇｙ株式会社 喫煙具用カートリッジ
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體ｒｎａ調配物之製備及儲存
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
EP4472673A1 (en) 2022-02-02 2024-12-11 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024160826A1 (en) 2023-01-31 2024-08-08 BioNTech SE Compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013786A (en) 1997-08-22 2000-01-11 Hybridon, Inc. MDM2-specific antisense oligonucleotides
PL1633327T3 (pl) 2003-06-04 2011-02-28 Univ Georgetown Sposób poprawienia stabilności i okresu trwałości kompleksów liposomowych
EP1512393A1 (de) 2003-09-08 2005-03-09 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
CA2649630C (en) 2006-04-20 2016-04-05 Silence Therapeutics Ag Lipoplex formulations for specific delivery to vascular endothelium
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20110319473A1 (en) * 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
US20150272885A1 (en) * 2011-10-14 2015-10-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2830593B1 (en) * 2012-03-26 2019-02-27 BioNTech RNA Pharmaceuticals GmbH Rna formulation for immunotherapy
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
US12263229B2 (en) 2014-11-10 2025-04-01 Ethris Gmbh Induction of osteogenesis by delivering BMP encoding RNA
HRP20260181T1 (hr) * 2017-10-20 2026-03-27 BioNTech SE Priprema i skladištenje lipozomskih rnk formulacija koje su pogodne za terapiju
WO2020200472A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy

Also Published As

Publication number Publication date
US12433911B2 (en) 2025-10-07
DK3946255T3 (da) 2025-01-06
EP3946255B1 (en) 2024-11-20
CA3134211A1 (en) 2020-10-08
CO2021013376A2 (es) 2021-10-20
CN113924082B (zh) 2024-07-05
BR112021020011A2 (pt) 2021-12-14
IL285811A (en) 2021-10-31
WO2020201383A1 (en) 2020-10-08
WO2020200472A1 (en) 2020-10-08
US20220143069A1 (en) 2022-05-12
CN113924082A (zh) 2022-01-11
ZA202106237B (en) 2023-06-28
SG11202109164WA (en) 2021-10-28
JP7692837B2 (ja) 2025-06-16
MX2021012138A (es) 2021-11-03
CL2021002557A1 (es) 2022-05-20
JP2022527830A (ja) 2022-06-06
EP3946255A1 (en) 2022-02-09
AU2020255262A1 (en) 2021-09-23
ES3008537T3 (en) 2025-03-24
KR20210148162A (ko) 2021-12-07

Similar Documents

Publication Publication Date Title
AR127361A2 (es) Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
BR112022011956A2 (pt) Composições de concentrado de suspensão de diamida
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
AR094583A1 (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizante y métodos para elaborar y usar los mismos
IN2015MU00865A (es)
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
CL2019002478A1 (es) Formulación de anticuerpo monoclonal anti-vrs.
AR088380A1 (es) Formulaciones de etanercept estabilizadas con cloruro de sodio
MX2020004578A (es) Composiciones de casz y metodos de uso.
PE20212265A1 (es) Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos
AR123677A1 (es) Preparación y almacenamiento de formulaciones de rna liposomal adecuadas para terapia
PE20150964A1 (es) Formulaciones acuosas estables de adalimumab
MX2021002935A (es) Formulacion de anticuerpos contra csf-1r.
AR070356A1 (es) Producto para cuidado oral y metodos de uso del mismo
CL2022001989A1 (es) Formulación de anticuerpos estable
MX2020005857A (es) Formulaciones de composiciones de vacuna contra el virus del dengue.
MX2023008333A (es) Nanomateriales.
HRP20250792T1 (hr) Formulacije anhidriranog natrij tiosulfata
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
MX2022011071A (es) Composiciones que mejoran la estabilidad del poxvirus.
UY38153A (es) Formulaciones acuosas estables de anticuerpos anti-tau